Stock Analysis
Summit Therapeutics Inc. Common StockSMMT
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsBuy24 analystsPrice is 16% of the way from the year's low to its high.
Cash covers 67% of debt · FY 2022.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Financial Health75
Risks
- Valuation20
- Growth0
Weak fundamentals at a demanding price.
Market context
-4.8% today· Z 1.4σ
Bull Case
- ✓Altman Z 49.4 — safe-zone balance sheet
What's happening with SMMT
Profile
Strong financial health; growth, profitability, earnings quality, moat and valuation lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-4.0%)0/25
- P/S (12878.9x)0/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (-135.9%)0/25
- Net margin (-9027.1%)0/25
- Operating margin (-8108.3%)0/25
- Financial Health75/100 · Strong
- Altman Z (49.44)25/25
- Current ratio (6.96)25/25
- Interest coverage (-121.3x)0/25
- Net cash / debt (Net cash)25/25
- Quality0/100 · Weak
- Piotroski F (1/9)0/25
- Beneish M (n/a)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 3736.6%)0/25
- Moat0/100 · Weak
- ROIC >12% years (0/3 yrs)0/25
- Median gross margin (n/a)0/25
- FCF-positive years (0/6 yrs)0/25
- Worst-year net margin (worst -11174.8%)0/25
Risk Flags
- ⚠6 loss-making years in recent history
- ⚠Interest coverage -121.3× — thin debt cushion
About Summit Therapeutics Inc. Common Stock
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Show more
Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Headquarters: MIAMI, FL · Employees: 265 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-4.0%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -26.9%–-0.4% · 43rd pct
P/S (TTM)12878.93xD
Grade D: ExpensivePrice / TTM Revenue (own statements)
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales12442.1xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio18.37xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-1.24A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-135.9%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-141.9%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-9027.1%D
Grade D: LowNet Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin—
Gross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+819.5%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score49.44A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio6.96xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio6.67xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-121.3xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT0.8xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.03xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt33.88xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
0EPiotroski F-Score1/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability3736.6%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.01xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Anand Bhaskar Filed | Anand Bhaskar | Grant / award | +100.0K | |
Zanganeh Mahkam Filed | Zanganeh Mahkam | BuyOpen market buy | +3.81M | |
DUGGAN ROBERT W Filed | DUGGAN ROBERT W | BuyOpen market buy | +3.81M | |
Soni Manmeet Singh Filed | Soni Manmeet Singh | BuyOpen market buy | +25.0K | |
Soni Manmeet Singh Filed | Soni Manmeet Singh | BuyOpen market buy | +25.0K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Zanganeh Mahkam Filed | Zanganeh Mahkam | BuyOpen market buy | +100.0K | |
DUGGAN ROBERT W Filed | DUGGAN ROBERT W | BuyOpen market buy | +100.0K | |
Anand Bhaskar Filed | Anand Bhaskar | Grant / award | +30.0K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years0/3 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/6 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-11174.8%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$0.87
Cash & short-term investments per share (Finnhub)
Book Value / Share$0.79
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$20.38M
Total debt obligations (short + long term)
Cash & Equiv.$690.68M
Cash and short-term investments
Net Debt$-670.29MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$629.98M
Shareholders' equity (book value)
Asset / Liability6.16xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$11.57B
Current Market Capitalization
Beta-1.67B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Summit Therapeutics Inc. Common Stock (SMMT)
SMMT is down 4.81% at the last close. Summit Therapeutics Inc. Common Stock meets only 1 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 49.44 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Company is effectively debt-free after netting cash.
- Interest coverage of -121.3× leaves little room for earnings shocks.
- Summit Therapeutics Inc. Common Stock posted a net loss in 6 of 6 available completed fiscal years (2020–2025).
- At a valuation score of 20/100, SMMT trades at a premium to its historical multiples.
See how SMMT ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all SMMT moves →Frequently Asked Questions about SMMT
What is the current Summit Therapeutics Inc. Common Stock (SMMT) stock price?
SMMT is trading at $14.63 at the last market close, down 4.81% on the session. PreMarketPrice tracks SMMT pre-market, intraday and after-hours prices.
Is SMMT stock a buy right now?
PreMarketPrice's quantitative model rates Summit Therapeutics Inc. Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is SMMT stock overvalued?
Summit Therapeutics Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Summit Therapeutics Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for SMMT. The Earnings section lists recent reports and updates as dates are announced.
What sector does Summit Therapeutics Inc. Common Stock operate in?
Summit Therapeutics Inc. Common Stock operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Summit Therapeutics Inc. Common Stock do?
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases.
About Summit Therapeutics Inc. Common Stock (SMMT) Stock
Summit Therapeutics Inc. Common Stock (SMMT) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Summit Therapeutics Inc. Common Stock is trading at $14.63, down 4.81% on the day with a market capitalization of $11.6 billion. The financial health score for SMMT is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for SMMT stock.
SMMT Stock Analysis & Key Metrics
On PreMarketPrice, you can track Summit Therapeutics Inc. Common Stock (SMMT) across multiple dimensions:
- Pre-market price & movement: Real-time SMMT stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for SMMT with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Summit Therapeutics Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for SMMT.
- Sector peers: Compare SMMT against 6 other healthcare stocks on key financial metrics.
Is SMMT a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Summit Therapeutics Inc. Common Stock (SMMT) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Summit Therapeutics Inc. Common Stock (SMMT) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.